Last reviewed · How we verify
NCT04622124
A Safety and Tolerability Study of FCN-207 in Healthy Volunteers
Phase 1 trial testing Placebo in Hyperuricemia in 132 participants. Completed in 7 June 2022.
21 December 2021
Quick facts
| Lead sponsor | Fochon Pharmaceuticals, Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 132 |
| Start date | 11 November 2020 |
| Primary completion | 21 December 2021 |
| Estimated completion | 7 June 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Placebo
- fasted vs. high-fat meal
- Placebo
Conditions studied
- Hyperuricemia — all drugs for Hyperuricemia →
Sponsor
Fochon Pharmaceuticals, Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with Hyperuricemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is studying an investigational drug called FCN-207 in healthy adult males or females.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Review of Urate-Lowering Therapeutics: From the Past to the Future.
Jenkins C, Hwang JH, Kopp JB, Winkler CA, et al · · 2022 · cited 38× · PMID 36081938 · DOI 10.3389/fphar.2022.925219
Verify or expand the search:
- PubMed search for NCT04622124
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperuricemia
Currently open trials in the same condition.
- NCT07144332 — This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Ord · recruiting
- NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
- NCT06859073 — A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia · Phase 1 · recruiting
- NCT06463561 — CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea · Phase 4 · recruiting
- NCT06729853 — PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function · Phase 1, PHASE2 · active not recruiting
Other Fochon Pharmaceuticals, Ltd. trials
Trials by the same sponsor.
- NCT05212987 — Study of FCN-098 in Patients With Advanced Solid Tumor · Phase 1 · unknown
- NCT04682808 — A Study of FCN-338 in Patients With Chronic CLL/SLL · Phase 1 · active not recruiting
- NCT04687423 — Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II） · Phase 1 · unknown
- NCT03951116 — Study of FCN-437c in Patients With Advanced Solid Tumors · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04622124 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fochon Pharmaceuticals, Ltd.
- Last refreshed: 5 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04622124.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing